Previous 10 | Next 10 |
Earnings news remained a key theme during Tuesday's midday trading. Squarespace (NYSE:SQSP) and Oak Street Health (NYSE:OSH) both dropped following the release of their quarterly updates. Meanwhile, Turning Point Therapeutics (NASDAQ:TPTX) got a boost after it reported better-than-expected re...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +84%, Allied Healthcare Products (NASDAQ:AHPI) +39%, IMV (NASDAQ:IMV) +29%, Exagen (NASDAQ:XGN) +26%, Myomo (NYSE:MYO) +22%. Losers: SmileDirectClub (NASDAQ:SDC) -23%, EyeGate Pharmaceutica...
Shares of Fulcrum Therapeutics (NASDAQ: FULC) , an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial readout. Investors excited about the company's sickle-cell disease candidate pushed the stock 76% higher as of 10:35 a.m. EDT o...
Are Analysts Right About These Hot Stocks? Whether you’re talking about penny stocks, blue-chips, or meme stocks, traders focus on 1 thing. That is how to make money in the stock market right now. Thanks to the rise of companies like AMC Entertainment ( NYSE: AMC ), attention...
– Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology – – Company plans to initiate enrollment in a Phase 1b clinic...
Achieved dose proportional pharmacodynamic changes in HBG mRNA and F-reticulocytes in whole blood Mean 4.5-fold induction in HBG mRNA at 10mg after 14 days of once-daily dosing Mean 4.2-fold increase in F-reticulocytes at 10mg after 14 days of once-daily dosing ...
CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2021 financial results...
PM Images/DigitalVision via Getty Images Stifel is reiterating a buy rating on shares of Fulcrum Therapeutics (FULC) and doubling its price target from $20 to $39 following phase 2 data today on the company's candidate for fascioscapulohumeral muscular dystrophy. That price target assume upsi...
Fulcrum Therapeutics (FULC) announces results from its Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy ((FSHD)).FSHD is a serious, rare, progressive and disabling disease, characterized by muscle degeneration and fat infiltration, initially affecting movemen...
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not met Losmapimod showed statistically significant* (p < 0.05) and clinically relevant benefit across multiple structural, functional and patient reported...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...